There is a relatively small segment of leaders in the business world; individuals with leadership and the ability to leverage their knowledge and education to achieve aggressive goals while building trust and relationships and rapport and motivating forward momentum to achieve goals.
Jim Berlanti, MD is one of those professionals, who throughout his career possess a proven record of success driving results through collaboration, partnerships, and relationships as both an Internist with his peers and a Medical Strategist in the healthcare industry. With enthusiasm Jim radiates a sincere passion for delivering value and benefits to agencies, clients and business units.
As the Chief Medical Officer for one of the world’s largest healthcare agencies, Jim created and led a scientific team and a global network of expert advisors, which consistently identified untapped opportunities through market analysis and led to the success of numerous category leaders including Crestor, Enbrel, Seroquel, Prilosec/Nexium and Ambien. Jim’s role was expanded to uncover insights across brands and agencies, worldwide, for the worlds largest healthcare communications network Publicis Healthcare. He was part of the global new business team G7.
He was part of the Saatchi/Pharmacia team that was instrumental in working with FDA and KOLs redefining a category, OAB, for Detrol, when Detrol did not meet it’s primary endpoint.. OAB was created specifically as a consumer driven term. OAB developed into a multi-billion dollar category.
In 2008, Saatchi and Saatchi were named “Agency of the Year”. As part of the Saatchi management team he also was part of the global new business team. Jim devoted 60-70 % of his time to new business pitches across all promotional venues. In 2009 Saatchi won 29 new business pitches.
Jim’s expertise and experience across virtually every therapeutic category is current as are the insights he has, he has the ability to see the commercial opportunity within evolving market dynamics, and he has an unmatched network of experts who will speak to him with more authenticity peer to peer because of their respect for him.
From an Internist’s perspective, Jim brings advanced medical knowledge and insight to the MD audiences, with the documented ability to communicate current and future medical trends, within the physician and pharmaceutical communities. He has expert insights into all the specialties, both at the KOL level, as well as the PCP and the community specialists, by market. He has the ability to speak about the disease states across categories. Jim has built a very large network of key opinion leaders and academic community physicians across many specialties and global marketplaces. He also has a working knowledge of FDA and other regulatory agencies.
Jim joined Havas World Wide in April of 2014 as SVP Medical Director. He worked on a new PCSK9 monoclonal antibody that is coming to market for hyperlipidemia. His other responsibilities included working as an internal consultant across the global network. He went on to work at Noven Pharmaceuticals, Harrison & Star and Ogilvy where he was part of the Agency/Client Xeljanz team, due to his category experience, having launched Enbrel and basically having touched every new entry into that space.
Jim holds a Bachelor of Arts in science from the College of the Holy Cross and a Doctor of Medicine from Mt. Sinai Icahn School of Medicine in New York City. After completing his residency in Internal Medicine at Mt. Sinai Icahn School of Medicine at Elmhurst, Jim served as a staff and faculty member at NYU/Bellevue Hospital Medical Center for two years. He then moved into Advertising.
With many key accomplishments, Jim has more than 27 year of success Agency side supporting customer centric agencies bridging the gap between agencies, physicians and pharmaceutical companies focusing on current and future product trends supported by successful communications assisting agencies in reaching and exceeding their revenue goals.
Dr. Sotirios Stergiopoulos is Senior Vice President and Head of Global Medical Affairs and a member of the R&D Leadership team at Ipsen BioScience. Sotirios has a extensive experience in directing medical affairs worldwide strategies and plans and a solid expertise in Oncology drug development that includes chemotherapy, immunology drugs and targeted agents across various tumor indications. Sotirios’ past experience includes Vice President, Head of Global Medical Affairs Oncology at Baxalta (now Shire, Cambridge, MA), Executive Medical Director Oncology US Medical Affairs at Celgene Corporation (Summit, NJ), Senior Global Brand Medical Director Oncology at Novartis Pharmaceuticals (East Hanover, NJ) and Director Medical Affairs Oncology at Bayer Healthcare (Montville, NJ).
Dr. Stergiopoulos earned his M.D at the University of Medical Sciences of Poznan, Poland. He completed his residency in Internal Medicine at the Albert Einstein College of Medicine (NY), a clinical and research fellowship in Medical Genetics at Harvard Medical School and a research fellowship at National Institutes of Health where he had received an Intramural Research Training Award.
Dr. Stergiopoulos is currently an Attending Physician in the Department of Internal Medicine at Jacobi Medical Center, Albert Einstein College of Medicine (NY). In addition, he holds a Masters in Biotechnology Enterprise and Entrepreneurship (MBEE) from The Johns Hopkins University (Baltimore, MD). Sotirios is a Fellow of the New York Academy of Medicine as well as the Royal Society of Medicine (UK). He also is a Member of the American Association of Cancer Research, American Society of Clinical Oncology, and sits on multiple Boards as well as Chairman of Board of A2A Pharmaceuticals, a fragment based computational drug design company.
Dr. Robin Winter-Sperry is currently the Head of Global Field Based Medical Excellence & Insights, Sanofi Genzyme in Cambridge, MA. She started working in the industry in the area of Dermatology at Schering-Plough (now Merck). She has had a long and distinguished career including Sanofi/Genzyme Global Medical Affairs, Strategy & Tactics in the area of Multiple Sclerosis and President and CEO of Scientific Advantage, LLC. She created Novartis’ Medical Science Liaison (MSL) department of Scientific Operations and Sanofi-Synthelabo’s Medical Therapeutic Liaison division. She has been involved in over 28 product launches. She has pioneered the recognition of MSLs as a specialty in the biopharmaceutical and device industry and is responsible for creating and developing many of the industry’s leading Medical Affairs and Medical Liaison teams.
Sam Rasty is an associate professor of Clinical & Administrative Sciences at the California Northstate University College of Pharmacy (CNUCOP). He received his Doctor of Pharmacy degree from the Ferris State University. After graduation, Dr. Rasty completed a Cardiovascular Pharmacotherapy Fellowship at Henry Ford Hospital in Detroit, MI. Dr. Rasty was the clinical coordinator in cardiac and medical intensive care unit at Advocate Christ Medical Center and since 2004 has held various academic, and pharmaceutical industry positions in Medical and Regulatory affairs prior to joining CNUCOP. Most recently Dr. Rasty completed a Master’s degree in public health with a focus in epidemiology. Dr. Rasty’s research primarily focuses on patient health outcomes in cardiovascular pharmacotherapy.
Marianne Kenny, PharmD is a senior level medical affairs executive in the pharmaceutical industry with over 27 years of experience. She has had extensive experience leading global processes and technology initiatives within the medical information, promotion review, publication planning, knowledge management, grants and investigator-initiated trials, integrating and streamlining these functions each time a new company was acquired. Marianne is an accomplished leader with a track record of building corporate value and leveraging strong industry acumen. She has expertise in assembling high-performance teams and providing the leadership and guidance that meets synergy targets and continuing functionality of medical departments under corporate integrity agreements. She has worked with several organizations including Grunenthal Pharmaceuticals, Watson, Actavis, and Allergan Pharmaceuticals as Vice President of Global Medical Communications and Professional Affairs. Currently she is with Bayer in Medical Affairs. She holds a Doctor or Pharmacy degree from the University of the Sciences.
Dr. Kanmaz has served on the faculty at St. John’s University, College of Pharmacy and Health Sciences since 1996 with an interim three-year appointment as an HIV Clinical Science Manager at Abbott Laboratories. During her time at Abbott, she served as the HIV clinical expert for the 5 boroughs of New York, attended national and international HIV/AIDS conferences, developed and presented post-conference educational slide decks, collaborated on phase IV investigator-initiated studies, developed key opinion leaders, participated in regional advisory board meetings, and supported the sales and marketing teams.
She is currently the Assistant Dean for Experiential Pharmacy Education and Associate Clinical Professor in the Department of Clinical Health Professions. She has received several grants directed toward the care of patients with HIV/AIDS and disadvantaged persons in high poverty situations. She is certified as an American Academy of HIV Medicine HIV Expert as well as a certified Smoking Cessation Counselor. Dr. Kanmaz is also an active member of several committees within the American Association of Colleges of Pharmacy10, Experiential Education Special Interest Group.
Dr. Mehul Patel has more than 11 years of experience within the pharmaceutical and medical communications industry. He is currently employed as a Director of Medical Affairs at Allergan, providing medical leadership for the cardiovascular, metabolic and psychiatry portfolio. Responsibilities include developing aligned global medical strategic plans and providing medical input into tactical activities within these therapeutic areas. He as has authored multiple publications and has conducted numerous live CME and non CME lectures. In addition to his current role, Mehul gained his medical affairs/communications experience at PDL BioPharma and at Embryon Inc.. In addition, he spent five years working as a clinical program lead at Biogen Idec where his responsibilities included constructing strategic clinical development plans for drug candidates in the cardiovascular, CNS and immunology therapeutic areas.
Dr. Patel received his doctorate in pharmacy at the Ernest Mario School of Pharmacy (Rutgers University).
Toll Free : 1-855-255-7137
55 Oak Street
Suite 201, Unit C
Norwood, NJ 07648 USA
Rio de Janieiro St 212, Suite 151
Sao Paulo, SP 01240-010 Brasil
202, Jai Omkar, Plot No. 36, Sector 20,
Airoli, Navi Mumbai, India - 400 708